• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Publication date: Available online 10 March 2016 Source:Cell Author(s): Weifei Zhu, Jill C. Gregory, Elin Org, Jennifer A. Buffa, Nilaksh Gupta, Zeneng Wang, Lin Li, Xiaoming Fu, Yuping Wu, Margarete Mehrabian, R. Balfour Sartor, Thomas M. McIntyre, Roy L. Silverstein, W.H. Wilson Tang, Joseph A. DiDonato, J. Mark Brown, Aldons J. Lusis, Stanley L. Hazen Normal platelet function is critical to blood hemostasis and maintenance of a closed circulatory system. Heightened platelet reactivity, however, is associated with cardiometabolic diseases and enhanced potential for thrombotic events. We now ...
Source: Cell - March 12, 2016 Category: Cytology Source Type: research

MassDevice.com +5 | The top 5 medtech stories for May 26, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Ortho Kinematics wins Health Canada nod for VMA system Ortho Kinematics said today it won Health Canada authorization for its Vertebral Motion Analysis spinal imaging system. The VMA system from Austin, Texas-based Ortho Kinema...
Source: Mass Device - May 26, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news

Outcomes of Cardiac Pacing in Adult Patients After a Fontan Operation
Conclusions More than one-third of adult Fontan patients referred to Mayo Clinic had pacemaker implantation. Epicardial leads were associated with high rate of pacemaker reinterventions but similar DRC rates in comparison to endocardial leads.
Source: American Heart Journal - August 26, 2017 Category: Cardiology Source Type: research

Left ventricular assist device exchange for the treatment of HeartMate II pump thrombosis.
Conclusions: It is generally feasible to treat pump thrombosis via LVAD exchange. Yet, the exchange procedure is not without risk and the risk of re-thrombosis (34%), stroke (29%), postoperative dialysis (29%) and perioperative complications remains high. PMID: 30034845 [PubMed]
Source: Journal of Thoracic Disease - July 25, 2018 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

FDA approves Abbott ’ s HeartMate 3 as a destination therapy
Abbott (NYSE:ABT) said today it won FDA approval for its HeartMate 3 left ventricular assist device, now approved as a destination therapy for patients with advanced heart failure. With the approval, the Chicago-based company said that the device can now be used in patients not eligible for a transplant as a life-long implant. “We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes. The unique design of the HeartMate 3 LVAD—with its Full MagLev technology—takes an established innovation and improves upon it in meaningful ways to help people with advanced he...
Source: Mass Device - October 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

Abbott & #039;s HeartMate 3 Pump Can Now be Offered as a Destination Therapy
As if Abbott Laboratories hasn't had enough to celebrate this year, the company just scored FDA approval for the use of its Heartmate 3 pump as a destination therapy. The approval, which CEO Miles White hinted about earlier in the week, is a big win for Abbott – and an even bigger win for advanced heart failure patients. The approval means that doctors can now offer the HeartMate 3 system to patients who are not eligible for a transplant. These patients will live with the device for the rest of their lives. For advanced heart failure patients who can no longer rely on earlier stage treatment o...
Source: MDDI - October 19, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Business Source Type: news

Natural Antibodies and Left Ventricular Assist Device Complications
Left ventricular assist devices (LVAD) are widely used as a bridge to heart transplantation or destination therapy for advanced heart failure. However, hemocompatibility-related complications such as pump thrombosis, stroke and bleeding remain frequent. We previously reported that LVAD implantation is followed by a sharp increase in serum levels of IgG natural antibodies (Nabs) recognizing oxidation-specific epitopes (OSE). Nabs have been implicated in inflammatory reactions related to atherosclerosis, ischemic stroke and primary graft dysfunction following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S.B. See, A. Pinsino, N. Kunimune, D. Onat, E. Hittesdorf, A.R. Garan, V.K. Topkara, N. Yoshifumi, H. Takayama, K. Takeda, P.C. Colombo, G. Wagener, M. Yuzefpolskaya, E. Zorn Tags: 606 Source Type: research

Peak Left Atrial Appendage Emptying Velocity Remains Reduced in Atrial Fibrillation during Continuous Flow Left Ventricular Assist Device Support
Although regions of stasis such as the left atrial appendage (LAA) may be potential sites of thrombus formation during atrial fibrillation (AF), its thrombotic contribution during high flow mechanical unloading is unknown. Moreover, registry studies only show a mixed association of AF and stroke during continuous flow left ventricular assist device (CF LVAD) support. Since a lower peak Left Atrial Appendage Emptying Velocity (LAAEV) of less than 40 cm/s during AF, mechanistically contributes to thrombosis and stroke in non-CF LVAD populations, we sought to evaluate the LAAEV in CF LVAD patients with and without AF.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: A. Rahman, E. Tam, L. ZHeng, J. Fontes, S. Forest, S. Vukelic, D. Sims, J. Shin, S. Patel, D.J. Goldstein, U.P. Jorde, O. Saeed Tags: 88 Source Type: research

Increased Mean Platelet Volume is Associated with Decreased Survival in Patients Supported with Impella
Increased mean platelet volume (MPV) has been associated with elevated risk of stroke and myocardial infarction in the general population and stroke/pump thrombosis in Heartmate II recipients. It has been proposed that contact with foreign surfaces and centrifugation promote prothrombotic states with platelet activation and increased MPV. An association between MPV and outcomes of patients treated with percutaneous short-term circulatory devices has not been investigated.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: M. Harutyunyan, K. Doshi, H. Nazeer, E. Joye, O. Saeed, M. Torosoff, U. Jorde, D. Belov Tags: (1029) Source Type: research

Huge thrombus formation in the left ventricle during bilateral CentriMag ventricular assist device with successful bridging to heart transplantation: a case report and review of the literature
AbstractOwing to shortage of donor hearts, the ventricular assist device is used as a bridging therapy to heart transplantation. However, thrombus formation is a critical complication during ventricular assist device circulatory support that might result in ischemic infarction of end organs. Here, we report a patient diagnosed with decompensated dilated cardiomyopathy and cardiogenic shock who underwent emergent extracorporeal life support, and subsequent temporary bilateral ventricular assistance with the CentriMag device (Levitronix LLC, Waltham, MA). Daily transthoracic echocardiography did not detect any thrombus forma...
Source: Journal of Artificial Organs - July 13, 2020 Category: Transplant Surgery Source Type: research

A Comparative Analysis of Long-Term Outcomes in the MOMENTUM 3 Pivotal Trial and Continued Access Protocol Post-Approval Study Phase: A Study of over 1500 HeartMate 3 Implants
The MOMENTUM 3 pivotal trial conducted from 2014 to 2018 evaluated safety and effectiveness of the HeartMate 3 (HM3) left ventricular assist system (LVAS) compared to the HeartMate II pump. The trial demonstrated superiority of the HM3 LVAS for the primary endpoint of survival free of disabling stroke or reoperation to replace a malfunctioning pump at 2-years. HM3 LVAS superiority was due to improved hemocompatibility with near-elimination of device thrombosis, halving of stroke rates, and a decrease in gastrointestinal bleeding rates compared to the control device.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: M.R. Mehra Tags: (4) Source Type: research

Outflow cannula position for left ventricular assist device: A propensity score ‐matched study
ConclusionNo observed difference in mortality when adjusting for competing risk of heart transplantation. There was also no difference in stroke, pump thrombosis, driveline infection. Larger studies are required to confirm these findings. These preliminary data support the use of left-sided anastomoses to facilitate subsequent re-entry during heart transplantation.
Source: Journal of Cardiac Surgery - August 25, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Khalil Jawad, Frank Koziarz, Alex Koziarz, Joanna N. Bouez, Naoto Fukunaga, Michael A. Borger, Vivek Rao Tags: ORIGINAL ARTICLE Source Type: research

Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin
Cardiovascular disease (CVD) as defined by the American Heart Association includes ischaemic heart disease, stroke, heart failure and thromboembolism [1]. Solid organ transplantation is associated with an increased risk of CVD morbidity and mortality [2], a relationship which was first observed in the context of kidney transplantation by Foley in 1998 [3]. This manifests clinically as an increased rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, non-fatal myocardial infarction, non-fatal stroke, unstable angina and heart failure [4,5].
Source: Heart, Lung and Circulation - November 27, 2021 Category: Cardiology Authors: Afolarin A. Otunla, Kumaran Shanmugarajah, Maria Lucia Madariaga, Alun H. Davies, Joseph Shalhoub Tags: Editorial Source Type: research

1 Ventricular assist devices: developments in asia and global outlook for the next 10 years
The advent of left ventricular assist systems to support patients with advanced-stage heart failure has been a 50 year odyssey, now available broadly to such patients.1 Engineering advances have ushered in an era of small, durable devices that can be fully implanted within the chest. Yet, haemocompatibility related adverse events, which emanate from the interaction between the device and the patient they support are manifest principally in increased stroke rates, de novo device thrombosis requiring replacement and in gastrointestinal bleeding (a peculiar adverse event resulting from the unnatural physiology of continuous f...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Mehra, M. R. Tags: Keynote Lecture Source Type: research

Identifying patients at risk: multi ‐centre comparison of HeartMate 3 and HeartWare left ventricular assist devices
ConclusionsHM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2  years of implantation. Additional research using post-operative variables is warranted to identify which HVAD patients need an upgrade to HM3 or expedited transplantation.
Source: ESC Heart Failure - February 17, 2023 Category: Cardiology Authors: Lieke Numan, Daniel Zimpfer, Osnat Itzhaki Ben Zadok, Emmeke Aarts, Michiel Morshuis, Sabina P.W. Guenther, Julia Riebandt, Dominik Wiedemann, Faiz Z. Ramjankhan, Anne ‐Marie Oppelaar, Tuvia Ben‐Gal, Binyamin Ben‐Avraham, Folkert W. Asse Tags: Original Article Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12